I-MAB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 EUR | 0.00% |
|
-8.97% | -12.88% |
| 06-06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
| 06-05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 823B | ||||||
| 627B | ||||||
| 353B | - | - | - | - | ||
| 320B | ||||||
| 295B |
- Stock Market
- Equities
- IMAB Stock
- 0VY Stock
- Charts I-Mab
- Sector Chart
